# REPLOT (NCT06408168)

> Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06408168
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Hormone Receptor-positive Human Epidermal Growth Factor 2-negative; Metastatic Invasive LObular Carcinoma
- Interventions: Fulvestrant; Repotrectinib
- Enrollment: 6
- Primary outcome: Safety and adverse events (AEs)

## Indexed commentary on REPLOT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=replot-nct06408168